In last trading session, Ikena Oncology Inc (NASDAQ:IKNA) saw 0.43 million shares changing hands with its beta currently measuring 0.24. Company’s recent per share price level of $1.80 trading at $0.31 or 20.81% at ring of the bell on the day assigns it a market valuation of $86.87M. That closing price of IKNA’s stock is at a discount of -324.44% from its 52-week high price of $7.64 and is indicating a premium of 43.33% from its 52-week low price of $1.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.61 million shares which gives us an average trading volume of 166.65K if we extend that period to 3-months.
For Ikena Oncology Inc (IKNA), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $iShares Genomics Immunology and in the current quarter.
Ikena Oncology Inc (NASDAQ:IKNA) trade information
Upright in the green during last session for gaining 20.81%, in the last five days IKNA remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $1.80 price level, adding 2.7% to its value on the day. Ikena Oncology Inc’s shares saw a change of -32.33% in year-to-date performance and have moved 23.29% in past 5-day. Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value. Analysts have been projecting $6.00 as a low price target for the stock while placing it at a high target of $11.00. It follows that stock’s current price would drop -511.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -233.33% for stock’s current value.
Ikena Oncology Inc (IKNA) estimates and forecasts
Statistics highlight that Ikena Oncology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -71.65% of value to its shares in past 6 months, showing an annual growth rate of 14.21% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -13.63% during past 5 years.
Ikena Oncology Inc is more likely to be releasing its next quarterly report on November 09 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Ikena Oncology Inc (NASDAQ:IKNA)’s Major holders
Insiders are in possession of 0.34% of company’s total shares while institution are holding 73.75 percent of that, with stock having share float percentage of 74.01%. Investors also watch the number of corporate investors in a company very closely, which is 73.75% institutions for Ikena Oncology Inc that are currently holding shares of the company. Orbimed Advisors LLC. is the top institutional holder at IKNA for having 9.4 million shares of worth $61.67 million. And as of Jun 29, 2023, it was holding 25.09% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 5.07 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 13.53% of outstanding shares, having a total worth of $33.26 million.
On the other hand, Fidelity Advisor Biotechnology Fund and Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 1.54 million shares of worth $7.94 million or 4.11% of the total outstanding shares. The later fund manager was in possession of 1.07 million shares on Jul 30, 2023, making its stake of worth around $5.51 million in the company or a holder of 2.86% of company’s stock.